Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-000802
Abstract: Gastro-oesophageal (GE) cancers are a heterogeneous disease that traditionally have been approached as a monolith. Data regarding the benefit of systemic chemotherapy among the anatomical, histological and molecular subgroups of GE cancers are sparse. The… read more here.
Keywords: systemic chemotherapy; oesophagogastric junction; chemotherapy; junction adenocarcinoma ... See more keywords
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Immunology Research"
DOI: 10.1155/2017/3970605
Abstract: Nampt including eNampt and iNampt may contribute to mediating obesity-associated cancers. This study investigated the role of Nampt in esophagogastric junction adenocarcinoma (EGA), a cancer strongly correlated with obesity. Visceral adiposity was defined by waist… read more here.
Keywords: junction adenocarcinoma; tnm stage; visceral adiposity; esophagogastric junction ... See more keywords
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
Sign Up to like & getrecommendations! Published in 2018 at "Case Reports in Gastroenterology"
DOI: 10.1159/000490906
Abstract: We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m2 intravenously… read more here.
Keywords: junction adenocarcinoma; long term; ramucirumab; gastroesophageal junction ... See more keywords
Clinical characteristics and prediction model of long time survival of patients with stage M1 Siewert type II esophagogastric junction adenocarcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Translational cancer research"
DOI: 10.21037/tcr-20-3291
Abstract: The incidence of adenocarcinomas of the esophagogastric junction are increasing in the whole wide world over the past two decades with a very poor 5-year overall survival for advanced esophagogastric junction adenocarcinoma (1-4). Siewert divided… read more here.
Keywords: junction adenocarcinoma; clinical characteristics; esophagogastric junction; junction ... See more keywords
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Future oncology"
DOI: 10.2217/fon-2020-1007
Abstract: Standard-of-care, first-line therapy for patients with advanced human epidermal growth factor receptor 2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma is chemotherapy plus trastuzumab, a monoclonal antibody (mAb) targeting HER2. Margetuximab is an Fc-optimized mAb that binds HER2. Retifanlimab,… read more here.
Keywords: junction adenocarcinoma; unresectable metastatic; gastroesophageal junction; her2 ... See more keywords
SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.977894
Abstract: Background Esophagogastric junction adenocarcinoma (EGJA) is a special malignant tumor with unknown biological behavior. PD-1 checkpoint inhibitors have been recommended as first-line treatment for advanced EGJA patients. However, the biomarkers for predicting immunotherapy response remain… read more here.
Keywords: immunotherapy response; junction adenocarcinoma; score; esophagogastric junction ... See more keywords
Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.993573
Abstract: Gastric and gastro-esophageal junction adenocarcinoma (GEA) remains a considerable major public health problem worldwide, being the fifth most common cancer with a fatality-to-case ratio that stands still at 70%. Angiogenesis, which is a well-established cancer… read more here.
Keywords: gastric gastro; junction adenocarcinoma; esophageal junction; gastro esophageal ... See more keywords
Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.998101
Abstract: Objective The standard treatment for stage II–III gastroesophageal junction adenocarcinoma (GEJA) remains controversial, and the role of radiotherapy (RT) in stage II–III GEJA is unclear. Herein, we aimed to evaluate the prognosis of different RT… read more here.
Keywords: junction adenocarcinoma; gastroesophageal junction; stage iii; stage ... See more keywords
Serum Insulin-Like Growth Factor Binding Protein 7 as a Potential Biomarker in the Diagnosis and Prognosis of Esophagogastric Junction Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Gut and Liver"
DOI: 10.5009/gnl19135
Abstract: Background/Aims Esophagogastric junction adenocarcinoma (EJA) is a malignant tumor associated with high morbidity and has attracted increasing attention due to a rising incidence and low survival rate. Pathological biopsy is the gold standard for diagnosis,… read more here.
Keywords: junction adenocarcinoma; like growth; insulin like; esophagogastric junction ... See more keywords
External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Contemporary Brachytherapy"
DOI: 10.5114/jcb.2017.69334
Abstract: Purpose The aim of this study was to retrospectively observe and analyze the long-term treatment outcomes of 96 elderly patients with gastroesophageal junction adenocarcinoma (GEJAC) who were treated with californium-252 (252Cf) neutron brachytherapy (NBT) in… read more here.
Keywords: junction adenocarcinoma; patients gastroesophageal; treatment; gastroesophageal junction ... See more keywords
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Gastric Cancer"
DOI: 10.5230/jgc.2023.23.e15
Abstract: Purpose Liver metastasis (LM) is reported in approximately 40% of patients with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma (metastatic esophagogastric adenocarcinoma; mGEA) and is associated with a worse prognosis. This post-hoc analysis from the RAINBOW trial reported… read more here.
Keywords: ram pac; junction adenocarcinoma; gastroesophageal junction; liver metastasis ... See more keywords